Percentage reduction from baseline in clinicopathological measures of response (prior systemic therapy pooled safety population, patients with baseline assessment data available). (A) Bone marrow mast cell infiltrates (median percent). (B) Serum tryptase (ng/mL). (C) KIT D816V VAF (median percent). (D) Spleen volume (mL).